Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Price Not Available 10mg Rebastinib (DCC-2036) Supplier Page

Trivial name	N/A
Catalog Number	S2634
Molecular Formula	C30H28FN7O3
CAS#	1020172-07-9
Inchi	InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)
Inchi Key	WVXNSAVVKYZVOE-UHFFFAOYSA-N
SMILES	CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5
Size	10mg
Supplier Page	http://www.selleckchem.com/products/dcc-2036.html
Additional Information	https://file.selleck.cn/downloads/struct/DCC-2036-chemical-structure-s2634.gif